Public trial registry of the CCC-Munich

Trial CLL 17

Trial Trial design Status In-/Exclusion Therapy Participants Documents Permissions Tumorboards

Trial
World
Trial acronym
:
CLL 17
World
Full title
:

A phase 3 multicenter, randomized, prospective, open-label trial of ibrutinib monotherapy versus fixed-duration venetoclax plus obinutuzumab versus fixed-duration ibrutinib plus venetoclax in patients with previously untreated chronic lymphocytic leukemia (CLL)

World
NCT number
:
World
Responsible organization
:
3. Med 3. Med Ismaninger Str. 22 81675 München Germany
Indications
Classification Code Description
- Bloodcancer (leukemia, lymphoma)
Trial design
World
Phase
:
III
Status
World
Status
:
Recruitment finished
Votes
Initiiation & lock
World
Date of lock (planned / actual)
:
Unknown / Unknown
Therapy
World
Therapy line
:
1
World
Therapy
:

Zielgerichtet

Participants
Function Prename Surname Organization
World Responsible contact Simon Heidegger 3. Med 3. Med Ismaninger Str. 22 81675 München Germany Magnifier